<DOC>
	<DOCNO>NCT01395732</DOCNO>
	<brief_summary>The effect bosentan digital ulcer ( DU ) study two randomized placebo-controlled trial ( RAPIDS-1 RAPIDS-2 ) . A limitation study heterogeneous study population . More importantly , endpoint assess change vasculopathy / perfusion . Laser Doppler image show effectively demonstrate blood flow restriction hand patient Systemic Sclerosis ( SSc ) . The relation blood flow restriction hand measure laser Doppler image extent DU disease study . The current study attempt demonstrate relation . In addition , impact bosentan blood flow hand , define cohort SSc-DU patient history DU within past 2 year clinically relevant reduction blood flow hand , assess .</brief_summary>
	<brief_title>Bosentan Systemic Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>Male female subject &gt; 18 year diagnose SSc ; Reduction blood flow measure laser Doppler imaging , least 50 % , distally proximal interphalangeal joint , compare healthy volunteer ; Women childbearing potential must negative pregnancy test use reliable form contraception ; A history 1 DUs within 2 year prior inclusion ; No use bosentan past ; Subjects willing able sign inform consent . Parenteral prostanoid treatment DU &lt; 3 month ago ; Chronic treatment PDE5 inhibitor ERA ; History bosentan use Irreversible significant limitation hand function , e.g . amputation one finger ; Other type system connective tissue disease ; Significant peripheral ( macro ) vascular disease due e.g . diabetes , hyperlipidemia , uncontrolled systemic hypertension , coagulopathy ; Any serious medical co morbidity ( eg , active malignancy ) subject life expectancy &lt; 12 month ; Known AST and/or ALT elevations high 3 time Upper Limit Normal ( ULN ) ; Moderate severe liver function disorder ; Pregnancy breastfeeding ; Treatment Glibenclamide , Fluconazole , Cyclosporin A , Tacrolimus calcineurin inhibitor ; Hypersensitivity bosentan one component ; Subjects able follow protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>